Bronchodilator effects of indacaterol and formoterol in patients with COPD.
about
Combined aclidinium bromide and long-acting beta 2 -agonist for COPDSafety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.Indacaterol (arcapta neohaler) for chronic obstructive pulmonary diseaseIndacaterol: a comprehensive review.Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.An update on the use of indacaterol in patients with COPD.Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.Indacaterol: a novel long-acting β(2) -agonist.Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.Indacaterol for the treatment of chronic obstructive pulmonary disease.
P2860
Q24187613-87BDF2B4-D583-4F3A-93BC-8A2A29C0AB38Q34544020-CF6F1EA3-C8BF-4947-83AA-BD62C1FA12E6Q35822146-59893E55-5995-4C8C-867F-475E49D95872Q35958673-6E1C6058-BBFD-47DA-82BF-0A13DA32272FQ37057061-54E6927A-E2DF-4E3E-8BB7-CA137BC66413Q37773997-0FE16AEE-7DE7-4BD8-ABEB-4D09127FAB20Q37804908-B12B36B5-820D-4E27-B64A-581AD5E03ABFQ37808058-A222ED5E-D255-4CE3-96EE-9B3587C694E5Q37846698-7D0E3961-2B62-4A10-953A-FCC86A29FD68Q37911291-F09CF763-3FA2-4964-AAB6-E3EDDB88AE28Q37987211-E9BBE7D7-99D7-47DA-8F33-FD6479B966D7Q37999465-84889FA7-9E06-4696-859E-98314BCFE251Q38002357-A1B6A847-DA7F-4ED8-B99E-9DA26C8F31A6Q38248438-42D8CB2E-E4FE-4BB0-8B15-A263DC2A6F63Q41908094-E5B155A5-8A3D-4773-9DB1-EE40A60814A8Q42170464-78B208C7-0B13-4673-A9A1-BC84400A7158Q48059168-3482D396-6FD7-44FF-9028-A916CA809BE5
P2860
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@ast
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@en
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@nl
type
label
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@ast
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@en
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@nl
prefLabel
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@ast
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@en
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@nl
P2093
P1476
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
@en
P2093
P304
P356
10.1016/J.PUPT.2009.05.001
P577
2009-05-22T00:00:00Z